Guggenheim Maintains Buy on Genmab, Raises Price Target to $42
Guggenheim analyst Michael Schmidt maintains Genmab (NASDAQ:GMAB) with a Buy and raises the price target from $40 to $42.
Read original at benzingaStocks · News reference
Genmab shares are trading higher after Guggenheim raised its price target on the stock from $40 to $42.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 7, 2026, 6:11 PM
- Checked
- Aug 7, 2026, 6:11 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Genmab Raises FY2026 Sales Guidance from $4.065B-$4.395B to $4.325B-$4.525B vs $4.355B Est
Genmab (NASDAQ:GMAB) raises FY2026 sales outlook from $4.065 billion-$4.395 billion to $4.325 billion-$4.525 billion vs $4.355 billion estimate.
Read original at benzingaGenmab shares are trading lower after the company and AbbVie provided clarification on the primary endpoints from the Phase 3 EPCORE DLBCL-1 study. The study did not meet its primary endpoint.
Read original at benzinga